Immunocompromised patients — including those with HIV infection or active malignancy — represent a distinct and more challenging population when managing oral candidiasis. The degree of immune compromise shapes both the risk of more generalised disease and the adequacy of standard therapeutic approaches.
This protocol addresses oral candidiasis occurring in the setting of immunocompromised states, including HIV infection or cancer. In these patients, standard regimens alone may prove insufficient — particularly when infection involves resistant strains — and the clinical picture can extend beyond localised disease.
The protocol specifies systemic antifungal therapy from the triazole class, with options selected for activity against resistant strains. The complete regimen — including which agent, under what conditions, and the criteria for selection — is detailed in the full structured protocol.
DOI: 10.1136/pmj.78.922.455
Furthermore, when dealing with immunocompromised patients, such as those HIV-infected, or cancerous, this drug has good effects doubling the dose.
In spite of knowing the efficacy of the drugs listed above, when it comes to a more generalized candidiasis or immunocompromised patients, these would not be sufficient.
But when fluconazole failed, itraconazole was prescribed to these patients, having good results.
In that case it will be used other drugs like itraconazole or newest ones as voriconazole.
The new triazol antifungal voriconazole [200 mg per day] has been shown to be a potent drug.
View source ↗